Primary care physicians criticized for weak response to opioid addiction

The sharp increase in opioid abuse and the resulting deaths hasn’t led to a strong response from primary care physicians, even though they could recognize problems in patients earlier, according to a recent article by STAT News.

The piece said primary care doctors “follow an old script” of referrals to addiction and drug treatment centers rather than taking more proactive steps, such as getting certified for addiction treatments like buprenorphine.

“We’re just watching the ship sink, even though we have the pumps to easily keep the water out,” R. Corey Waller, MD, MS, who leads the advocacy division of the American Society of Addiction Medicine, told STAT.

Waller cautions that he’s not blaming primary care physicians, saying they’ve been set up to fail, though some have resisted calls to become more educated on identifying and treating addiction.

“I’ve had conversations with a few hundred primary care doctors to try to figure this out,” Waller said. “I get comments like, ‘I don’t want those people in my waiting room.’ Ones who are more well-meaning—which is most—say they have no training to treat this disease.”

For more on why physicians say they don’t have the time to get certified and why major medical groups like the American Medical Association oppose making training mandatory, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.